BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ...
Study presented at SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism About YTX-7739YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Yumanity Therapeutics, a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs ...
Glioblastoma cells rely on the conversion of carbohydrates to fats to support the cells’ energy demands. An investigational drug called YTX-7739 interferes with this process When given to mice with ...
The results indicate that YTX-7739 actively engages with its intended target, SCD, in the mouse brain. The observed improvements in pathology and neuron survival, and the resultant correction of motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback